FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lesley Murray

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Phenomena

Phosphorylation

Physiology

Co-author Network

Publications

TOP 3
JC Young; S Wu; G Hansteen; C Du; Lidia C Sambucetti; Stacy W Remiszewski; Anne-Marie O'Farrell; B Hill; C Lavau; Lesley J Murray
Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.
Tinya J Abrams; Lesley J Murray; Enrico Pesenti; Vicky Walker Holway; Tina Colombo; Leslie B Lee; Julie M Cherrington; Nancy K Pryer
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lesley Murray (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: JC Young; S Wu; G Hansteen; C Du; Lidia C Sambucetti; Stacy W Remiszewski; Anne-Marie O'Farrell; B Hill; C Lavau; Lesley J Murray
Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.
Cytotherapy 2004;6(4):328-36.
2003: Tinya J Abrams; Lesley J Murray; Enrico Pesenti; Vicky Walker Holway; Tina Colombo; Leslie B Lee; Julie M Cherrington; Nancy K Pryer
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Molecular cancer therapeutics 2003;2(10):1011-21.
2003: Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Molecular cancer therapeutics 2003;2(5):471-8.
2003: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
2003: Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne-Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Clinical & experimental metastasis 2003;20(8):757-66.
2003: Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):327-37.
1999: Lesley J Murray; JC Young; L J Osborne; KM Luens; Roland Scollay; BL Hill
Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division.
Experimental hematology 1999;27(6):1019-28.
1999: JC Young; K Lin; G Hansteen; MA Travis; Lesley J Murray; L Jaing; Roland Scollay; BL Hill
CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo.
Experimental hematology 1999;27(6):994-1003.
1998: Lesley J Murray; KM Luens; M F Estrada; E Bruno; Ronald Hoffman; R L Cohen; M A Ashby; Saroj Vadhan-Raj
Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis.
Experimental hematology 1998;26(3):207-16.
1998: KM Luens; MA Travis; B P Chen; BL Hill; Roland Scollay; Lesley J Murray
Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin- cells with preserved ability to engraft SCID-hu bone.
Blood 1998;91(4):1206-15.
1997: Saroj Vadhan-Raj; Lesley J Murray; Carlos E Bueso-Ramos; Shreyaskumar Patel; Sekhar M Pothireddy; W Keith Hoots; T Johnston; Nicholas Papadopolous; W N Hittelman; DA Johnston; T A Yang; V E Paton; R L Cohen; Sue Hellmann; Robert S Benjamin; Hal E Broxmeyer
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.
Annals of internal medicine 1997;126(9):673-81.
1996: JC Young; E Bruno; KM Luens; S Wu; M Backer; Lesley J Murray
Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34+ progenitor cells from single CD34+Thy-1+Lin- primitive progenitor cells.
Blood 1996;88(5):1619-31.
1994: Anne Galy; S Webb; D Cen; Lesley J Murray; J Condino; R S Negrin; B P Chen
Generation of T cells from cytokine-mobilized peripheral blood and adult bone marrow CD34+ cells.
Blood 1994;84(1):104-10.